isatin
versatil
lead
molecul
design
potenti
antivir
agent
isatin
deriv
display
broad
spectrum
pharmacolog
properti
includ
cytotox
reddi
et
al
alcaid
et
al
antibacteri
akhaja
raval
antifung
reddi
et
al
antivir
kang
et
al
bacani
et
al
sin
et
al
antihiv
bal
et
al
antimalari
han
et
al
activ
first
clinic
approv
antivir
agent
methisazon
activ
smallpox
vaccinia
virus
bauer
n
thiosemicarbazon
deriv
isatin
inhibitori
replic
teitz
ronen
inhibitor
japanes
enceph
viru
infect
sebastain
et
al
gener
configur
isatin
molecul
resembl
purin
also
tryptophan
deriv
evid
avail
whether
act
antimetabolit
compound
bauer
sadler
recent
studi
shown
isatin
could
inhibit
proteas
caspas
mao
enzym
medvedev
et
al
viral
pathogen
respons
mani
human
diseas
exampl
diseas
caus
virus
includ
common
cold
smallpox
aid
cold
sore
human
herp
viru
papilloma
viru
etc
pradoprado
et
al
worldwid
market
antivir
drug
estim
approxim
billion
us
dollar
expect
grow
rapidli
new
therapi
becom
avail
need
effect
antivir
drug
emphas
lack
vaccin
respiratori
tract
viru
infect
adenoviru
rhinoviru
parainfluenza
viru
respiratori
syncyti
viru
rsv
wide
occur
human
papilloma
virus
herp
simplex
viru
hsv
varicellazost
viru
vzv
viru
cytomegaloviru
cmv
vast
array
hemorrhag
fever
virus
de
clercq
million
peopl
worldwid
affect
infecti
diseas
caus
virus
widespread
viral
resist
renew
interest
quest
new
antivir
agent
earlier
work
could
clearli
defin
structur
requir
necessari
retent
antivir
activ
heterocycl
thiosemicarbazon
neurovaccinia
infect
mice
viral
infect
primarili
affect
respiratori
gastrointestin
system
epithelium
mucou
membran
endothelium
skin
mouth
genit
lymphoid
tissu
liver
organ
central
nervou
system
bruce
et
al
recent
report
deriv
could
antimicrobi
antioxid
activ
kiran
et
al
thiosemicarbazon
first
antivir
compound
recogn
possess
broadspectrum
antivir
activ
rang
dna
rna
virus
castro
et
al
earlier
report
describ
antivir
activ
differ
viral
strain
quenel
et
al
pandeya
et
al
howev
biolog
activ
evalu
dna
rna
virus
connect
ongo
work
isatin
kiran
et
al
report
simpl
effici
method
synthesi
thiocarbohydrazon
thiocarbohydrazon
deriv
depict
scheme
compound
screen
vitro
antivir
activ
also
two
stage
mouseskin
carcinogenesi
test
melt
point
mp
determin
open
capillari
use
toshniw
melt
point
apparatu
express
uncorrect
ftir
spectra
kbr
record
thermo
nicolet
nexu
seri
nmr
spectra
record
mhz
dmsod
solvent
use
tm
intern
standard
chemic
shift
ppm
mass
spectra
obtain
lcmsdtrapsl
reaction
monitor
use
thin
layer
chromatographi
tlc
aluminumback
precoat
silica
gel
plate
e
merck
puriti
compound
check
silica
gelcoat
aluminum
sheet
tlc
column
chromatographi
perform
use
qualigen
silica
gel
mesh
solvent
ar
grade
distil
use
isatin
purchas
himedia
mumbai
india
obtain
e
merck
india
substitut
aldehyd
purchas
sd
fine
chemic
synthesi
isatin
deriv
carri
use
modifi
sandmey
methodolog
henri
blatt
nbenzyl
isatin
prepar
microwav
method
report
literatur
shmidt
et
al
isatin
deriv
exhibit
physic
properti
report
literatur
synthesi
thiocarbohydrazid
carri
taguchi
method
physic
data
synthes
compound
compar
show
mp
similar
report
literatur
zhou
et
al
equimolar
mixtur
thiocarbohydrazid
mol
substitut
aldehyd
mol
drop
glacial
acet
acid
taken
ml
ethanol
ml
conic
flask
result
mixtur
heat
reflux
h
reaction
mixtur
cool
overnight
precipit
collect
filtrat
purifi
recrystal
ethanol
synthes
compound
compar
report
literatur
moham
et
al
solut
monothiocarbohydrazon
mol
substitut
isatin
mol
ethanol
drop
glacial
acet
acid
ad
initi
reaction
progress
reaction
monitor
tlc
residu
cool
kept
overnight
precipit
collect
filtrat
solid
purifi
column
chromatographi
subsequ
recrystal
ethanol
mixtur
thiocarbohydrazid
carbohydrazid
mol
mix
appropri
substitut
isatin
deriv
mol
acid
reaction
mixtur
reflux
h
reaction
mixtur
cool
kept
overnight
precipit
collect
filtrat
result
solid
purifi
column
chromatographi
subsequ
recrystal
ethanol
ir
br
lactam
w
ar
co
lactam
cs
cn
cc
dmsod
ppm
nh
nh
nh
nh
nch
dd
j
hz
td
j
hz
j
hz
nmr
dmsod
ppm
cs
co
cn
mass
mz
mna
element
analysi
calcul
c
h
n
found
c
h
n
ir
w
ar
co
lactam
cs
cn
chn
dmsod
ppm
nh
dd
j
hz
dd
j
hz
mass
mz
element
analysi
calcul
c
h
n
found
c
h
n
ir
w
ar
str
co
lactam
cs
cn
chn
dmso
ppm
dd
j
hz
dd
j
hz
mass
mz
mna
element
analysi
calcul
c
h
n
found
c
h
n
ir
w
ar
co
lactam
cs
cn
chn
dmsod
ppm
dd
j
hz
dd
j
hz
mass
mz
mna
element
analysi
calcul
c
h
n
found
c
h
n
ir
ar
co
lactam
dmso
ppm
dd
j
hz
dd
j
hz
td
j
hz
mass
mz
element
analysi
calcul
c
h
n
found
c
h
n
ir
ar
co
cs
dmsod
ppm
td
j
hz
mass
mz
element
analysi
calcul
c
h
n
found
c
h
n
ir
ar
co
lactam
ar
oop
dmsod
ppm
mass
mz
mna
element
analysi
calcul
c
h
n
found
c
h
n
ir
nh
nh
ar
co
lactam
cc
ar
co
cn
dmsod
ppm
mass
mz
mna
element
analysi
calcul
found
c
h
n
ir
nh
nh
ar
co
lactam
cc
ar
co
cn
dmsod
ppm
mass
mz
mna
element
analysi
calcul
n
found
c
h
n
ir
nh
ar
ch
str
co
co
lactam
cc
ar
cn
dmsod
ppm
mass
mz
mna
element
analysi
calcul
c
h
n
found
c
h
n
ir
nh
ar
co
co
lactam
cc
ar
cn
dmsod
ppm
mass
mz
element
analysi
calcul
c
h
n
found
c
h
n
ir
nh
nh
co
cn
ncsn
dmsod
ppm
mass
mz
element
analysi
calcul
c
h
n
found
c
h
n
synthes
compound
evalu
antivir
activ
accord
wellestablish
procedur
de
clercq
compound
evalu
antivir
activ
use
follow
virus
human
cytomegaloviru
hcmv
strain
davi
herp
simplex
viru
type
strain
ko
thymidin
kinasedefici
tk
ko
strain
resist
acv
acvr
herp
simplex
viru
type
strain
g
vaccinia
viru
vesicular
stomat
viru
vsv
vzv
strain
oka
tk
vzv
strain
rsv
strain
long
vsv
coxsacki
parainfluenza
sindbi
punta
toro
felin
coronaviru
fipv
felin
infecti
periton
viru
influenza
viru
subtyp
influenza
b
viru
antivir
assay
carri
felin
kidney
cell
felin
corona
viru
felin
herp
viru
hela
cell
cultur
vesicular
stomat
viru
coxsacki
viru
rsv
human
embryon
lung
hel
cell
cultur
ko
g
vaccinia
viru
vesicular
stomat
viru
tk
ko
acvr
madin
darbi
canin
kidney
mdck
cell
influenza
subtyp
influenza
subtyp
influenza
b
vero
cell
cultur
viru
sindbi
viru
coxsacki
viru
punta
toro
viru
hel
vero
hela
cell
line
use
studi
monitor
mycoplasma
contamin
found
mycoplasmafre
confluent
cell
cultur
microtit
plate
inocul
viru
viru
dose
infect
cell
cultur
plaqu
form
unit
pfu
vzv
cell
cultur
incub
presenc
vari
concentr
test
compound
viral
cytopath
plaqu
format
vzv
record
soon
reach
complet
control
virusinfect
cell
cultur
treat
test
compound
antivir
activ
express
compound
concentr
requir
reduc
virusinduc
cytopath
viral
plaqu
format
cytostat
activ
base
inhibit
hel
cell
growth
hel
cell
seed
cellswel
microtit
plate
allow
prolifer
h
medium
contain
differ
concentr
test
compound
ad
day
incub
cell
number
determin
coulter
counter
cytostat
concentr
calcul
compound
concentr
requir
reduc
cell
growth
rel
number
cell
untreat
control
valu
estim
graphic
plot
number
cell
percentag
control
function
concentr
test
compound
cytotox
express
minimum
cytotox
concentr
mcc
compound
concentr
caus
microscop
detect
alter
cell
morpholog
synthes
compound
evalu
antivir
activ
three
influenza
viru
subtyp
apuerto
ahong
bhong
antivir
activ
estim
inhibitori
effect
virusinduc
cytopath
effect
determin
microscop
examin
andor
formazanbas
mt
cell
viabil
test
effect
concentr
concentr
produc
inhibit
virusinduc
cytopath
effect
determin
visual
score
cpe
measur
cell
viabil
colorimetr
formazanbas
mt
assay
cytotox
test
compound
express
compound
concentr
caus
minim
chang
cell
morpholog
mcc
concentr
caus
cytotox
determin
mt
assay
specif
pathogenfre
femal
icr
mice
week
old
bodi
weight
approx
g
obtain
japan
slc
inc
shizuoka
japan
anim
hous
five
per
polycarbon
cage
temperaturecontrol
room
given
food
water
ad
libitum
throughout
experi
anim
divid
three
experiment
group
contain
mice
back
mous
shave
surgic
clipper
mice
topic
treat
benz
anthracen
dmba
nmol
aceton
ml
initi
treatment
one
week
initi
papilloma
format
promot
twice
weekli
applic
tpa
nmol
aceton
ml
skin
fig
one
hour
treatment
tpa
mice
treat
sampl
nmol
aceton
ml
incid
papilloma
examin
weekli
period
week
tanaka
et
al
percentag
mice
bear
papilloma
fig
averag
number
papilloma
per
mous
fig
record
novel
aldehyden
bisisatin
evalu
variou
strain
dna
virus
ie
human
cytomegaloviru
hcmv
vaccinia
viru
vacv
hsv
type
type
acyclovirresist
acvr
vzv
tabl
test
compound
also
evalu
sever
rna
virus
ie
vsv
coxsacki
viru
rsv
parainfluenza
viru
type
sindbi
viru
punta
toro
viru
tabl
calcul
effect
concentr
compound
decreas
percentag
formazan
product
compound
treat
virusinfect
cell
produc
compoundfre
uninfect
cell
cytostat
concentr
calcul
concentr
requir
reduc
cell
growth
mcc
minimum
cytotox
concentr
caus
microscop
detect
alter
cell
morpholog
hel
vero
hela
cell
line
use
studi
regularli
monitor
mycoplasma
contamin
found
mycoplasmafre
antivir
activ
measur
twelv
isatin
deriv
use
cellprotect
assay
data
record
tabl
moder
activ
compound
strain
hcmv
although
concentr
close
toxic
level
specif
antivir
effect
note
evalu
compound
strain
ko
strain
g
acv
resist
ko
strain
vaccinia
viru
vesicular
stomat
viru
coxsacki
viru
respiratori
syncyti
viru
viru
sindbi
viru
punta
toro
viru
none
compound
exhibit
specif
antivir
effect
ie
minim
antivir
effect
concentr
fivefold
lower
minim
cytotox
concentr
virus
evalu
antiinfluenza
viru
activ
seri
isatin
deriv
determin
measur
inhibitori
effect
viru
replic
mdck
cell
use
three
strain
influenza
subtyp
antivir
data
obtain
microscop
evalu
virusinduc
cpe
confirm
mt
cell
viabil
assay
express
cytotox
compound
express
mcc
compound
concentr
caus
minim
alter
cell
morpholog
estim
microscopi
compound
concentr
caus
reduct
cell
viabil
base
mt
assay
none
twelv
analog
abl
inhibit
cytopath
effect
three
influenza
viru
subtyp
ie
influenza
b
tabl
except
show
activ
nontox
concentr
present
studi
select
two
compound
among
ten
compound
examin
effect
vivo
twostag
carcinogenesi
use
mouseskin
papilloma
induc
dmba
initi
tpa
promot
test
signific
toxic
effect
inflamm
lesion
damag
edema
eros
ulcer
observ
area
mous
skin
topic
treat
test
compound
experi
bodi
weight
anim
affect
treatment
test
compound
shown
fig
posit
control
dmba
tpa
group
papillomabear
mice
appear
rapidli
week
reach
within
week
promot
hand
treatment
compound
nmol
along
dmbatpa
reduc
percentag
papillomabear
mice
week
thereaft
week
reach
week
shown
fig
posit
control
group
number
papilloma
per
mous
form
increas
rapidli
week
reach
papillomasmous
week
hand
mice
treat
compound
bore
papillomasmous
period
week
moder
protect
observ
compound
percentag
papilloma
increas
rapidli
week
reach
week
group
papilloma
form
per
mous
week
promot
result
inhibitori
effect
compound
mous
twostag
carcinogenesi
induc
dmba
tpa
appar
potent
compound
thu
demonstr
vivo
antitumor
promot
activ
compound
show
stronger
chemoprevent
activ
compound
result
suggest
isatin
lead
molecul
may
use
cancer
chemoprevent
agent
synthes
twelv
compound
react
substitutedunsubstitut
thiocarbohydrazidecarbohydrazid
alcohol
presenc
glacial
acet
acid
synthes
compound
character
ftir
nmr
mass
spectra
compound
screen
antivir
activ
variou
strain
dna
rna
virus
exhibit
moder
antivir
activ
compar
refer
compound
anticarcinogen
activ
compound
examin
two
stagecarcinogenesi
test
use
dmba
initi
tpa
promot
data
suggest
compound
exhibit
stronger
chemoprevent
activ
compound
thu
result
suggest
isatin
lead
molecul
could
also
use
cancer
chemoprevent
agent
